CNC vs. HUM, MOH, ELV, IDXX, ALC, MRNA, GEHC, TAK, HLN, and IQV
Should you be buying Centene stock or one of its competitors? The main competitors of Centene include Humana (HUM), Molina Healthcare (MOH), Elevance Health (ELV), IDEXX Laboratories (IDXX), Alcon (ALC), Moderna (MRNA), GE HealthCare Technologies (GEHC), Takeda Pharmaceutical (TAK), Haleon (HLN), and IQVIA (IQV). These companies are all part of the "medical" sector.
Centene (NYSE:CNC) and Humana (NYSE:HUM) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, community ranking, dividends, earnings, analyst recommendations, valuation and risk.
Centene received 126 more outperform votes than Humana when rated by MarketBeat users. Likewise, 73.24% of users gave Centene an outperform vote while only 64.15% of users gave Humana an outperform vote.
Centene currently has a consensus price target of $85.25, indicating a potential upside of 15.20%. Humana has a consensus price target of $424.50, indicating a potential upside of 38.77%. Given Humana's higher possible upside, analysts plainly believe Humana is more favorable than Centene.
In the previous week, Humana had 24 more articles in the media than Centene. MarketBeat recorded 63 mentions for Humana and 39 mentions for Centene. Centene's average media sentiment score of 0.68 beat Humana's score of 0.34 indicating that Centene is being referred to more favorably in the media.
Centene has a beta of 0.38, suggesting that its stock price is 62% less volatile than the S&P 500. Comparatively, Humana has a beta of 0.45, suggesting that its stock price is 55% less volatile than the S&P 500.
93.6% of Centene shares are held by institutional investors. Comparatively, 92.4% of Humana shares are held by institutional investors. 0.3% of Centene shares are held by company insiders. Comparatively, 0.3% of Humana shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Humana has a net margin of 1.82% compared to Centene's net margin of 1.75%. Humana's return on equity of 17.76% beat Centene's return on equity.
Centene has higher revenue and earnings than Humana. Centene is trading at a lower price-to-earnings ratio than Humana, indicating that it is currently the more affordable of the two stocks.
Summary
Humana beats Centene on 10 of the 18 factors compared between the two stocks.
Get Centene News Delivered to You Automatically
Sign up to receive the latest news and ratings for CNC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CNC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
